Video

Rare Disease Day: What it means for the future of inherited retinal diseases

Aleksandra Rachitskaya, MD, discusses how the treatment landscape for inherited retinal diseases has changed and her hope for the future.

On Rare Disease Day, Aleksandra Rachitskaya, MD, talks about how far treatment has come for inherited retinal diseases. Once an untreatable diagnosis, inherited retinal diseases now have an approved gene therapy option as well as more therapeutics under investigation.

Video transcript

Dr. Rachitskaya: Hi, my name is Aleksandra Rachitskaya, and I'm a retina surgeon at Cleveland Clinic Cole Eye Institute.

On this Rare Diseases Day, I'm really excited about the future of Inherited Retinal Diseases. It used to be that Inherited Retinal Diseases were a type of diagnosis one was given, and there was not much hope in terms of treatment. A lot of patients would progressively lose vision and had to rely on low vision devices.

But these days, we do have an approved gene therapy, and also a lot of clinical trials focusing on gene therapy for a variety of Inherited Retinal Diseases.

So on this Rare Disease Day, I think the future of Inherited Retinal Diseases as it comes to gene therapy is bright, and I'm excited to be part of that.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.